Device Trial Radar · NCT06704906
Adult Patient Outcomes After Spine Surgery With Fibergraft BG Putty/Viper Prime
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
18
Actual
Start
Dec 20, 2024
Primary completion
May 2, 2026
Study completion May 2, 2026
Sponsor
- Lead sponsor
- University of PittsburghAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- DePuy Synthes
- First posted
- Nov 26, 2024
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Viper Prime/Expedium spine systems are intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion in the treatment of acute and chronic instabilities or deformities of the thoracolumbar and sacral spine. The Fibergraft Bioactive Glass (BG) is engineered to mimic the body's natural bone healing process. While previous studies have compared the use of Viper prime/Expedium spine system in minimally invasive and open surgeries, these studies did not specifically study the clinical and radiographic outcomes of patients who have received these implants in addition to Fibergraft. We aim to recruit patients with degenerative disc disease, spondylolisthesis, trauma, and/or pseudarthrosis who require spine surgery under standard of care and use these implants. We will then follow these patients for a duration of two years to report their clinical and radiographic outcomes to determine fusion, complication rate, and revision surgeries if any.
Conditions
- Spondylolisthesis, Lumbar Region
- Spinal Trauma With Neurological Deficit
- Degeneration of Lumbar Intervertebral Disc
Interventions
Use of Viper Prime/Expedium system with Fibergraft BG PuttyDevice
Patients who require spine surgery under standard of care and meet the inclusion and exclusion criteria identified, will be recruited from clinic. Consent for participation in study will be signed at the same time as consent for surgery. All PROMs and scans will be done as standard of care and data will be obtained through chart review for this study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- FusionTime frame: 2 years (At baseline, postoperatively at 6 weeks, 3 months, 6 months, 12 months, and 24 months)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.